Current Situation
- Current Market Price: ~₹165–171
- 52-Week Range: ₹132 – ₹221
- Business is transitioning from a slowdown phase to a recovery phase in its CDMO segment.
- Management expects early-to-mid-teen revenue growth over the next 2–3 years, supported by improving biotech funding and increasing demand for complex drug manufacturing.
Analyst Target Prices
| Source | Target Price |
|---|---|
| Consensus (11 Analysts) | ₹203 |
| Trendlyne Consensus | ₹225 |
| ICICI Direct | ₹220 |
| Motilal Oswal | ₹190 |
| Highest Analyst Target | ₹255 |
My Technical & Fundamental Targets
| Time Horizon | Target Price |
|---|---|
| 3 Months | ₹185–195 |
| 6–12 Months | ₹210–225 |
| 2–3 Years | ₹260–320 |
| Bull Case (Strong CDMO Recovery) | ₹350+ |
These targets assume:
- CDMO growth returns.
- EBITDA margins recover toward historical levels.
- Revenue growth reaches management's guided range.
- No major regulatory setbacks.
Key Levels
| Level | Price |
|---|---|
| Strong Support | ₹150–160 |
| Immediate Resistance | ₹190 |
| Major Resistance | ₹220 |
| Breakout Zone | Above ₹220 |
A sustained move above ₹220 could open the path toward ₹250–280 over the next 12–18 months.
Investment View
For investors accumulating now (₹165–170 range):
- Conservative Target: ₹203
- Base Case Target: ₹220–225
- Optimistic Target: ₹255+
- Stop Loss (positional): ₹148
Risk–Reward
| Scenario | Return Potential |
|---|---|
| ₹203 Target | ~20% |
| ₹225 Target | ~33% |
| ₹255 Target | ~50% |
Based on current valuations and expected CDMO recovery, ₹220–225 appears to be the most realistic 12-month target, while ₹255 becomes achievable if earnings growth accelerates in FY27.
Overall Rating: ⭐⭐⭐⭐☆ (8/10)
Target Price (12 Months): ₹220–225
Suitable for: Long-term investors willing to wait for the CDMO recovery cycle.
0 Comments